Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Inhibikase Therapeutics (IKT) Accumulated Depreciation & Amortization (2022 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Accumulated Depreciation & Amortization data on record, last reported at $117224.0 in Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 133.71% to $117224.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $117224.0, a 133.71% increase, with the full-year FY2024 number at $56725.0, up 86.27% from a year prior.
  • Accumulated Depreciation & Amortization reached $117224.0 in Q3 2025 per IKT's latest filing, up from $93537.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for IKT hit a ceiling of $170970.0 in Q2 2023 and a floor of $1681.0 in Q3 2022.
  • A 4-year average of $54854.8 and a median of $43590.0 in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 1320.88% in 2023, then tumbled 74.5% in 2024.
  • Tracing IKT's Accumulated Depreciation & Amortization over 4 years: stood at $6723.0 in 2022, then skyrocketed by 352.97% to $30453.0 in 2023, then soared by 86.27% to $56725.0 in 2024, then soared by 106.65% to $117224.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for IKT at $117224.0 in Q3 2025, $93537.0 in Q2 2025, and $69379.0 in Q1 2025.